IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 92.48

Change

+0.02 (+0.02)%

Market Cap

N/A

Volume

0.18M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.07 (+0.05%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

-0.08 (-0.12%)

USD 2.70B
FXH First Trust Health Care AlphaD..

-0.53 (-0.50%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

-0.83 (-0.98%)

USD 0.18B
IDNA iShares Genomics Immunology an..

-0.47 (-2.12%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.67 (-2.16%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.12 (+0.12%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.32 (-1.12%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-1.27 (-2.07%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-2.73%)

USD 6.67M

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.97 % 0.00 %

+1.39 (+0.97%)

USD 1.45B
XHC:CA iShares Global Healthcare.. 99.68 % 0.65 %

-0.08 (0.97%)

CAD 0.57B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.57% 90% A- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.57% 90% A- 83% B
Trailing 12 Months  
Capital Gain 0.34% 57% F 43% F
Dividend Return 1.40% 100% F 26% F
Total Return 1.73% 67% D+ 35% F
Trailing 5 Years  
Capital Gain 65.50% 57% F 51% F
Dividend Return 9.79% 79% B- 18% F
Total Return 75.28% 57% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 5.24% 67% D+ 51% F
Dividend Return 6.20% 71% C- 47% F
Total Return 0.96% 74% C 23% F
Risk Return Profile  
Volatility (Standard Deviation) 13.13% 76% C+ 71% C-
Risk Adjusted Return 47.23% 81% B- 60% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike